State of New Jersey Common Pension Fund D Has $1.90 Million Position in Inari Medical, Inc. (NASDAQ:NARI)

State of New Jersey Common Pension Fund D increased its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 23.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 46,087 shares of the company’s stock after purchasing an additional 8,830 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Inari Medical were worth $1,901,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in Inari Medical by 11.1% during the first quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock valued at $268,681,000 after acquiring an additional 561,562 shares in the last quarter. Point72 Asset Management L.P. raised its position in Inari Medical by 113.3% during the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock valued at $71,324,000 after acquiring an additional 786,691 shares in the last quarter. Armistice Capital LLC raised its position in Inari Medical by 353.1% during the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock valued at $48,595,000 after acquiring an additional 786,501 shares in the last quarter. American Century Companies Inc. raised its position in Inari Medical by 26.8% during the second quarter. American Century Companies Inc. now owns 980,917 shares of the company’s stock valued at $47,231,000 after acquiring an additional 207,485 shares in the last quarter. Finally, Bamco Inc. NY raised its position in Inari Medical by 27.4% during the first quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock valued at $37,288,000 after acquiring an additional 167,000 shares in the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Inari Medical

In other news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00. Following the sale, the director now owns 601,233 shares in the company, valued at approximately $27,067,509.66. This trade represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Mitch C. Hill sold 3,000 shares of Inari Medical stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total transaction of $135,390.00. Following the sale, the chief financial officer now owns 179,600 shares in the company, valued at $8,105,348. This represents a 1.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 126,000 shares of company stock worth $5,921,390. Insiders own 10.60% of the company’s stock.

Inari Medical Trading Up 2.7 %

Shares of Inari Medical stock opened at $50.56 on Monday. The company’s fifty day simple moving average is $45.19 and its 200-day simple moving average is $47.05. The company has a market cap of $2.96 billion, a price-to-earnings ratio of -37.45 and a beta of 0.96. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $67.13.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on NARI shares. Piper Sandler raised their price objective on shares of Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a research report on Tuesday, October 29th. Leerink Partnrs raised shares of Inari Medical to a “hold” rating in a research report on Tuesday, September 3rd. Canaccord Genuity Group lifted their price target on shares of Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Leerink Partners began coverage on shares of Inari Medical in a research report on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price target on the stock. Finally, Wells Fargo & Company dropped their price target on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Inari Medical presently has an average rating of “Hold” and a consensus price target of $58.89.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.